Skip to content

Anxiety: all studies

Page 208 of 772: studies 2,071 to 2,080 of 7,715, newest first. Back to the anxiety overview

Research

Ascorbic Acid and Esketamine for Mental Disorders in Women with Miscarriage: A Randomized Controlled Double-Blind Trial Protocol.

Neuropsychiatric Disease and Treatment 2025 Zhaojuan Ke, Ying Zhang, Binyang Cai et al. 1 citation

Pregnancy leads to vulnerabilities and susceptibilities to mental disorders. Miscarriage, as an adverse pregnancy outcome, and following curettage for treatment, add the risks of further psychiatric disorders, including depression, anxiety, insomnia, etc., and current approaches to prevention are unsatisfactory. Ketamine and its S-enantiomer esketamine can prevent postpartum depression, and...

Case Report: Successful management of psychogenic non-epileptic seizures with intranasal esketamine.

Frontiers in Psychiatry 2025 Muneeb Hashmi, Padmasini Mugunthan, Priyal Jain et al. 2 citations

Psychogenic non-epileptic seizures (PNES), or functional seizures (FS), are episodes that resemble epileptic seizures but may be psychological in origin. Unlike epileptic seizures, which are linked to abnormal electrical activity in the brain, functional seizures may be associated with psychological and/or physical distress, and do not show the same electrical patterns on an...

Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms.

Journal of Psychoactive Drugs 2025 Morgan Hadley, Alicia Halliday, James Stone 1 citation

Hallucinogen Persisting Perception Disorder (HPPD) is considered rare in hallucinogen users although there are conflicting reports about its incidence and prevalence. HPPD may be more common in those with trait neuroticism. In this study, we invited hallucinogen and other drug users to complete an online questionnaire about their use of hallucinogens, their experience of HPPD symptoms, and...

Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour.

Neuropharmacology 2025 James J Gattuso, Carey Wilson, Anthony J. Hannan et al. 10 citations

Psilocybin is a serotonergic psychedelic compound which shows promise for treating compulsive behaviours. This is particularly pertinent as compulsive disorders require research into new pharmacological treatment options as the current frontline treatments such as selective serotonin reuptake inhibitors, require chronic administration, have significant side effects, and leave almost half of the...

DOI: 10.1016/j.neuropharm.2024.110202 (opens in new tab) Full text (opens in new tab) Anxiety Psilocybin magic mushrooms Hallucinogens Psychedelics +5

Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder.

Journal of Pharmacology and Experimental Therapeutics 2025 Claire E Miller, Phillip R. Zoladz 10 citations

Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that develops following exposure to a traumatic event. Individuals with this condition experience numerous physiological and behavioral alterations, including intrusive memories, avoidance of trauma-related stimuli, heightened anxiety, hypervigilance, impaired cognition, elevated resting heart rate and blood pressure,...

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.

Neuropsychiatric Disease and Treatment 2025 Daniel A Kinderlehrer 13 citations

The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient of mushrooms in the...

Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.

Frontiers in Psychiatry 2025 Sofia Abramsky-Sze, Elliot Marseille, Richard Matzopoulos et al. 4 citations

Few population-based studies have examined associations between psychedelic use and mental health outcomes. This work describes characteristics of exclusive psychedelic mushroom use (referred to as PM use), PMs in combination with other psychedelic substances (multi-psychedelic or MP) use, and non-psychedelic use and explores mental health ratings in non-clinical settings. This work uses...

Is there a place for psychedelics in sports practice?

Acta Neuropsychiatrica 2025 Isabel Werle, Marina A. M. Portes, Leandro J Bertoglio 2 citations

Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use disorder, offering relatively safe profiles, enhanced efficacy, and lasting effects after a few applications. Athletes often experience high levels of stress and pressure, making them susceptible to these psychiatric conditions. However, the effects...

The psychosomatic impact of Yoga in medical education: a systematic review and meta-analysis.

Medical education online December 31, 2024 Sabyasachi Maity, Raman Abbaspour, Stephan Bandelow et al. 23 citations

Non-clinical approaches such as meditation, yoga, and mindfulness are popular traditional therapeutical interventions adopted by many educational institutions to improve the physical and mental well-being of learners. This study aimed to evaluate the effectiveness of yoga intervention in improving cardiopulmonary parameters such as blood pressure, heart rate, pulmonary function tests and...

Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design

Journal of Eating Disorders December 27, 2024 Elena Koning, Cristiano Chaves, Elisa Brietzke et al. 2 citations

Eating disorders (EDs) are a group of debilitating mental illnesses characterized by maladaptive eating behaviors and severe cognitive-emotional dysfunction, directly affecting 1-3% of the population. Standard treatments are not effective in approximately one third of ED cases, representing the need for scientific advancement. There is emerging evidence for the safety and efficacy of...